LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Accueil・Liste d'Actions・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Fermé

SecteurSoins de santé

2.28 0.44

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.27

Max

2.38

Chiffres clés
By Trading Economics
Revenu	2.6M -39M
Employés	150
EBITDA	-1.4M -39M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+282.02% upside

Dividendes
By Dow Jones
Prochains Résultats	13 mai 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	218M 780M
Ouverture précédente	1.84
Clôture précédente	2.28

Sentiment de l'Actualité

By Acuity

50%

175 / 346 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

1.18 / 1.69 Support & Résistance

Allogene Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 mai 2026, 22:15 UTC

Acquisitions, Fusions, Rachats

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 mai 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 mai 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11 mai 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 mai 2026, 22:32 UTC

Résultats

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 mai 2026, 22:02 UTC

Market Talk

Principaux Événements d'Actualité

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 mai 2026, 21:49 UTC

Résultats

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 mai 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 mai 2026, 21:31 UTC

Acquisitions, Fusions, Rachats

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 mai 2026, 21:23 UTC

Acquisitions, Fusions, Rachats

CSG Systems Sale to NEC Gets CFIUS Clearance

11 mai 2026, 21:12 UTC

Résultats

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 mai 2026, 21:12 UTC

Résultats

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11 mai 2026, 20:44 UTC

Résultats

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 mai 2026, 20:43 UTC

Résultats

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 mai 2026, 20:32 UTC

Résultats

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 mai 2026, 20:32 UTC

Résultats

CleanSpark 2Q Rev $136.4M >CLSK

11 mai 2026, 20:30 UTC

Résultats

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 mai 2026, 20:30 UTC

Résultats

Steris 4Q Cont Ops EPS $2.24 >STE

11 mai 2026, 20:30 UTC

Résultats

Steris 4Q Rev $1.6B >STE

11 mai 2026, 20:30 UTC

Résultats

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 mai 2026, 20:30 UTC

Résultats

Steris 4Q Adj EPS $2.83 >STE

11 mai 2026, 20:22 UTC

Actions en Tendance

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 mai 2026, 19:37 UTC

Résultats

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 mai 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Comparaison

Variation de prix

Allogene Therapeutics Inc prévision

Objectif de Prix

By TipRanks

282.02% hausse

Prévisions sur 12 Mois

Moyen 8.71 USD 282.02%

Haut 14 USD

Bas 3.85 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

1.18 / 1.69Support & Résistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

175 / 346Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.